1 active not recruiting, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Cellectis S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma UCART20x22, CLLS52 - B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1 / Phase 2 | Recruiting | Cellectis S.A. | 80 | 2022-11-01 | 2025-08-24 |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) UCART22, CLLS52 - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Cellectis S.A. | 45 | 2019-10-14 | 2026-11-09 |
Recurrence (2) · Burkitt Lymphoma (1) · Lymphoma, B-Cell (1)
Alemtuzumab (2)
France (2) · United States (2) · Spain (1)
Jeremy Abramson, MD (1) · Nitin Jain, MD (1)